Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$10.90
−HK$0.23 · -2.07%
Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Latest quote
HK$10.90
−HK$0.23 · -2.07%
Regular session · HKT · Market data may be delayed.
Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Day range
Current HK$10.90
52-week range
Current HK$10.90
Regular session · HKT · Market data may be delayed.
Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Day range
Current HK$10.90
52-week range
Current HK$10.90
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.21B CNY | 7.47B CNY | 8.01B CNY | 9.15B CNY | 8.34B CNY |
| Cost of goods sold | 2.34B CNY | 2.05B CNY | 1.94B CNY | 2.11B CNY | 2.09B CNY |
| Gross profit | 5.87B CNY | 5.42B CNY | 6.08B CNY | 7.04B CNY | 6.25B CNY |
| Research and development | 585.02M CNY | 329.98M CNY | 195.13M CNY | 125.43M CNY | 114.76M CNY |
| Selling, general, and administrative | 3.71B CNY | 3.44B CNY | 3.17B CNY | 3.36B CNY | 2.98B CNY |
| Operating expenses | 4.29B CNY | 3.69B CNY | 3.36B CNY | 3.39B CNY | 3.03B CNY |
| Interest income | 82.35M CNY | 126.34M CNY | 146.48M CNY | 105.52M CNY | 81.85M CNY |
| Interest expense | 20.3M CNY | 38.61M CNY | 46.25M CNY | 49.09M CNY | 28.27M CNY |
| Depreciation and amortization | 246.34M CNY | 259.24M CNY | 209.3M CNY | 209.08M CNY | 219.82M CNY |
| Operating income | 1.58B CNY | 1.73B CNY | 2.71B CNY | 3.55B CNY | 3.15B CNY |
| Net income | 1.49B CNY | 1.62B CNY | 2.4B CNY | 3.26B CNY | 3.02B CNY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.298
2025 complete year-46.8% since 2021
2026 partial: HK$0.344
HK$0.56
2,021
HK$0.616
2,022
HK$0.616
2,023
HK$0.25
2,024
HK$0.298
2,025
HK$0.344
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 28, 2026 | HK$0.189Semi-Annual | Aug 31, 2026 | Sep 8, 2026 |
Dividend | Apr 27, 2026 | HK$0.155Semi-Annual | Apr 28, 2026 | May 7, 2026 |
Dividend | Aug 29, 2025 | HK$0.171Semi-Annual | Sep 1, 2025 | Sep 9, 2025 |
Dividend | Apr 28, 2025 | HK$0.127Semi-Annual | Apr 29, 2025 | May 9, 2025 |
Dividend | Aug 29, 2024 | HK$0.164Semi-Annual | Sep 2, 2024 | Sep 9, 2024 |
Dividend | May 13, 2024 | HK$0.086Semi-Annual | May 14, 2024 | May 23, 2024 |
Ex-dividend Aug 28, 2026
HK$0.189
Semi-Annual
Record Aug 31, 2026 · Payment Sep 8, 2026
Ex-dividend Apr 27, 2026
HK$0.155
Semi-Annual
Record Apr 28, 2026 · Payment May 7, 2026
Ex-dividend Aug 29, 2025
HK$0.171
Semi-Annual
Record Sep 1, 2025 · Payment Sep 9, 2025
Ex-dividend Apr 28, 2025
HK$0.127
Semi-Annual
Record Apr 29, 2025 · Payment May 9, 2025
Ex-dividend Aug 29, 2024
HK$0.164
Semi-Annual
Record Sep 2, 2024 · Payment Sep 9, 2024
Ex-dividend May 13, 2024
HK$0.086
Semi-Annual
Record May 14, 2024 · Payment May 23, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS27.7M0.00%646.2B USD0.05%$86.04-1.26%
Vanguard FTSE Emerging Markets ETFVWO27.25M0.02%162.3B USD0.06%$59.61-1.23%
iShares Core MSCI Emerging Markets ETFIEMG19.63M0.01%163.33B USD0.09%$80.40-2.62%
Avantis Emerging Markets Equity ETFAVEM16.14M0.06%28.86B USD0.33%$93.14-2.32%
Global X China Biotech ETF (HKD)2820.HK6.2M1.12%646.32M HKD0.68%HK$72.16-1.02%
State Street SPDR Portfolio Emerging Markets ETFSPEM4.63M0.03%17.7B USD0.07%$51.93-1.10%
Vanguard FTSE All-World ex-US ETFVEU4.55M0.00%95.9B USD0.04%$84.09-1.28%
iShares Core MSCI Total International Stock ETFIXUS2.55M0.00%60.28B USD0.07%$95.95-1.31%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGAvantis Emerging Markets Equity ETFAVEMGlobal X China Biotech ETF (HKD)2820.HKState Street SPDR Portfolio Emerging Markets ETFSPEMVanguard FTSE All-World ex-US ETFVEUiShares Core MSCI Total International Stock ETFIXUSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
